Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cerus, Baxter to run another Intercept trial

CERS and partner Baxter (BAX) said post-market that they will run a

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE